• Drug Response Metrics in Cancer In Vitro

  2026-08-24

  Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its key practical contribution is a more resolved framework for separating growth inhibition from cell killing and interpreting their different proportions and timing in vitro.

• Separating Growth Arrest from Cell Death in Cancer Assays

  2026-08-24

  Schwartz’s dissertation reframes in vitro drug-response analysis by separating proliferative arrest from cell killing rather than treating both as a single viability outcome. This distinction improves interpretation of drug sensitivity, supports better time-course design, and helps researchers determine whether an apparent response reflects cytostasis, cytotoxicity, or a combination of both.

• Dovitinib (TKI-258) for ERK-Driven Cancer Studies

  2026-08-23

  Dovitinib (TKI-258) provides a practical perturbation tool for connecting RTK activity with ERK, STAT signaling, and apoptosis across cancer models. This guide translates melanoma pathway evidence into controlled workflows for multiple myeloma research, hepatocellular carcinoma treatment research, and broader RTK-driven studies.

• EPZ5676: DOT1L Biology to Translational Strategy

  2026-08-22

  A mechanistic and translational analysis of EPZ5676, a highly selective DOT1L inhibitor, connecting H3K79 methylation biology with MLL-rearranged leukemia research and emerging innate-immune insights in multiple myeloma.

• DOT1L Inhibition in Renal Fibrosis: Study Analysis

  2026-08-22

  The reference study identifies DOT1L and H3K79 dimethylation as injury-responsive regulators of renal fibroblast activation and epithelial–mesenchymal transition. Using a unilateral ureteral obstruction model, cultured renal cells, pharmacological inhibition, and siRNA, the authors show that blocking DOT1L suppresses several profibrotic pathways while preserving renoprotective factors.

• SGI-1027 and Everolimus in Renal Cancer

  2026-08-21

  A 2024 Advanced Science study identifies SGI-1027 as a methuosis-inducing agent that cooperates with everolimus in renal cancer models. The work links lysosomal membrane permeability to apoptosis and GSDME-dependent pyroptosis, providing a mechanistic strategy for addressing everolimus resistance.

• Dovitinib (TKI-258, CHIR-258) Lab Guide

  2026-08-20

  A scenario-based laboratory guide to using Dovitinib (TKI-258, CHIR-258), SKU A2168, in viability, proliferation, cytotoxicity, and pathway assays. It explains solvent handling, assay design, mechanistic interpretation, and practical criteria for selecting a reliable research-grade source.

• A-1331852: From BCL-XL Binding to Senolysis

  2026-08-20

  A-1331852 is a potent BCL-XL inhibitor for dissecting mitochondrial apoptosis, therapy-induced senescence, and apoptotic dependency. This guide translates mechanistic evidence into assay decisions while distinguishing biochemical affinity from cellular vulnerability.

• Chronic Cabozantinib Rewires RCC Phosphosignaling

  2026-08-19

  This study uses quantitative phosphoproteomics to distinguish acute from chronic Cabozantinib adaptation in renal cell carcinoma. It shows that prolonged exposure preserves MET activation-loop suppression while selectively remodeling adhesion-, stress-, and MAPK/AP-1-associated phosphorylation, with corresponding changes in migration and invasion.

• Cy5 NHS ester(Et): Practical Labeling Guide

  2026-08-19

  Cy5 NHS ester(Et) is a water-soluble, amine-reactive fluorescent reagent for covalently tagging proteins, peptides, and other biomolecules. This guide explains solvent selection, handling, cleanup, and assay QC while defining its limits, including incompatibility with ethanol and the lack of product-specific conditions for long-term solution storage.

• Relative Versus Fractional Viability in Cancer Drug Testing

  2026-08-18

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these readouts capture overlapping but nonidentical components of anticancer response. The framework helps researchers separate proliferative arrest from cell killing and interpret both response magnitude and timing more rigorously.

• Foretinib Assays: Separate Growth From Cell Death

  2026-08-18

  Foretinib (GSK1363089) can reveal more than a viability change when growth arrest, cell killing, motility, and metastasis are measured as distinct outcomes. This guide translates a key dissertation insight into a rigorous assay strategy for multikinase cancer research.

• Western Secondary Antibody Dilution Buffer Guide

  2026-08-17

  This scenario-based guide shows how Western Secondary Antibody Dilution Buffer, SKU K4115, can support more consistent protein detection when cell viability, proliferation, or cytotoxicity results require mechanistic validation. It covers compatibility, reuse, storage, interpretation, and practical vendor-selection criteria without overstating evidence.

• High-Density Bioprinting Models Hypoxic Glioblastoma

  2026-08-17

  Yao and colleagues developed a digital light processing bioprinted glioblastoma model in which cell density generates a reproducible, physiologically relevant hypoxic niche. The high-cell-density constructs showed marked HIF-1α enrichment and increased resistance to temozolomide, supporting their use for mechanistic studies and higher-throughput therapeutic screening.

• Imatinib (STI571) as a PDGFR Pathway Probe

  2026-08-16

  Imatinib (STI571) is more than a kinase inhibitor: it is a mechanistic reference for separating PDGFR activity from downstream remodeling phenotypes. This guide translates evidence from pulmonary vascular research into rigorous assay design and interpretation.

8064 records 1/538 page Next 12345 下5页 Last page